Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Good response to gefitinib in lung adenocarcinoma harboring coexisting EML4-ALK fusion gene and EGFR mutation.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Dec 2010

Kuo Yao-Wen, Wu Shang-Gin, Ho Chao-Chi, Shih Jin-Yuan

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Aged
Share to Antineoplastic Agents
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gefitinib

Share to Lung Neoplasms

Share to Oncogene Proteins, Fusion

Share to Quinazolines

Source

Identifiers

PMID: 21102267
DOI: 10.1097/JTO.0b013e3181f43274

Genes

ALK
EGFR
EML4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Good response to gefitinib in lung adenocarcinoma harboring coexisting EML4-ALK fusion gene and EGFR mutation.PMID 21102267Read ↗

Favorable response to gefitinib treatment of lung adenocarcinoma with coexisting germline and somatic epidermal growth factor receptor mutations.Semantic proximity Read ↗

Long-term response to gefitinib and crizotinib in lung adenocarcinoma harboring both epidermal growth factor receptor mutation and EML4-ALK fusion gene.Semantic proximity Read ↗

Lung adenocarcinoma with good response to erlotinib after gefitinib treatment failure and acquired T790M mutation.Semantic proximity Read ↗

Lung adenocarcinoma harboring concomitant EGFR mutation and EML4-ALK fusion that benefits from three kinds of tyrosine kinase inhibitors: a case report and literature review.Semantic proximity Read ↗

Coexistence of EGFR mutation and ALK translocation in NSCLC: literature review and case report of response to gefitinib.Semantic proximity Read ↗

Good response to gefitinib in a lung adenocarcinoma harboring a heterozygous complex mutation of L833V and H835L in epidermal growth factor receptor gene.Semantic proximity Read ↗

A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALK fusion gene.Semantic proximity Read ↗

Concomitant Epidermal Growth Factor Receptor Mutation and EML4-ALK Fusion in a Patient with Multifocal Lung Adenocarcinomas.Semantic proximity Read ↗

EGFR -mutant non-small cell lung cancer patients harboring CDK4 amplification show favorable response to afatinib: Two case reports.Semantic proximity Read ↗

EML4-ALK Translocation Predicts Better Outcome in Lung Adenocarcinoma Patients with Wild-Type EGFRSemantic proximity Read ↗

Experience with erlotinib in lung adenocarcinoma harboring a coexisting KIF5B-RET fusion gene and EGFR mutation: report of a rare case.Semantic proximity Read ↗

Concomitant EML4-ALK rearrangement and EGFR mutation in non-small cell lung cancer patients: a literature review of 100 casesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.